Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2020-04-20 | Katherine A. High, M.D. INDEPENDENT DIRECTOR Age: 68 COMMITTEES: None DIRECTOR SINCE: 2020 Katherine A. High, M.D., joined the Board in March 2020. Dr. High served as President of Spark Therapeutics, Inc. |
| 2021-04-16 | Katherine A. High, M.D., joined the Board in March 2020. Dr. High has served as President, Therapeutics of Asklepios Biopharmaceutical, Inc., a biotechnology and gene therapy company that is a wholly-owned subsidiary of Bayer AG, since January 2021. |
| 2022-04-29 | Katherine A. High, M.D., joined the Board in March 2020. Dr. High has served as President, Therapeutics of Asklepios Biopharmaceutical, Inc., a biotechnology and gene therapy company that is a wholly-owned subsidiary of Bayer AG, since January 2021. Dr. High served as President of Spark Therapeutics, Inc., a gene therapy company, from September 2014 until February 2020 and as Head of Research and Development of Spark from September 2017 until February 2020. From July 1999 through September 2014, Dr. High was a Professor at the Perelman School of Medicine at the University of Pennsylvania. From March 2003 through September 2014, Dr. High was an Investigator of the Howard Hughes Medical Institute. Dr. High served as the Director of the Center for Cellular and Molecular Therapeutics at Children’s Hospital of Philadelphia from September 2004 to April 2014. The Board has concluded that Katherine A. High should serve on the Board because she has significant executive, scientific and medical leadership experience, including extensive academic and industry experience in drug discovery and development. Her medical background, together with her experience leading drug discovery and development efforts at Spark Therapeutics, are expected to assist the Board in its oversight role over our drug discovery and development efforts. In addition, Dr. High has experience serving as an executive officer and director of publicly traded life sciences companies. Other Public Company Boards: Current CRISPR Therapeutics AG Past 5 Years Spark Therapeutics, Inc. (2014-2019) |
| 2023-04-28 | Katherine A. High, M.D., Independent Director, Former President, Therapeutics Asklepios Biopharmaceutical, Inc., Age: 71, Director Since: 2020, Committees: Science and Technology, 2022 Director Compensation Table: Total $454,968 |
| 2024-04-29 | Katherine A. High, M.D. INDEPENDENT DIRECTOR Age: 72 COMMITTEES: Science and Technology DIRECTOR SINCE: 2020 |
Data sourced from SEC filings. Last updated: 2025-12-07